Skip to main content
Review Article
Originally Published 16 May 2023
Free Access

AHA/ACC/HFSA Guidelines Implementation Case Series: Resynchronization Pacing Preferred in Patients With Reduced Ejection Fraction

A 68-year-old woman presented with 2 days of shortness of breath on exertion and fatigue. She denied syncope, chest pain, or leg swelling. She has known chronic obstructive pulmonary disease, type 2 diabetes, and hypertension. She underwent cardiac catheterization 1 year before this admission for concern for unstable angina, which showed nonobstructive coronary artery disease. She had normal left ventricular (LV) function by echocardiogram at that time and normal atrioventricular conduction. She has no known family history of cardiac disease or sudden death. She has no notable social history. She is on amlodipine and chlorthalidone for hypertension. Notable vitals included a pulse of 41 beats per minute and blood pressure 167/100. Physical examination was significant for nondistended jugular venous pressure with cannon a wave, variable S1, normal S2, and no murmurs. ECG revealed sinus rhythm, atrioventricular dissociation with ventricular escape rhythm at 36 bpm consistent with complete heart block (Figure 1).
Figure 1. Electrocardiogram on admission with sinus rhythm, atrioventricular dissociation with ventricular escape rhythm consistent with complete heart block.
Laboratories demonstrated potassium of 4.0, serum creatinine 1.0, undetectable troponin, normal thyroid stimulating hormone, and complete blood count. Transthoracic echocardiogram showed normal LV cavity size, mild LV hypertrophy with LV ejection fraction (EF) of 40% to 45%, mild global hypokinesis, normal right ventricular size, and function with no significant valvular abnormalities. The patient was diagnosed with Stage C heart failure with mildly reduced EF. Evaluation for potential etiologies of the ventricular dysfunction and bradycardia was unrevealing. The patient was planned for permanent pacemaker implantation along with guideline-directed medical therapy implementation.

Guideline Implementation

The patient underwent resynchronization pacemaker implantation for complete heart block and mildly reduced LV systolic function. She experienced improvement in her symptoms soon after the procedure. Electrocardiogram demonstrated sinus rhythm with biventricular paced complexes (Figure 2). Amlodipine was stopped and 25 mg of spironolactone was prescribed. Prior authorization for sacubitril-valsartan and an SGLT2i (sodium glucose transporter-2 inhibitor) was filed. Guidelines-based beta blocker therapy was delayed until the patients stabilized on pacing therapy.
Figure 2. Electrocardiogram postcardiac resynchronization therapy showing sinus rhythm with biventricular paced complexes.

Evidence

Based on the 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America guidelines for management of heart failure, in patients with a high-degree or complete heart block and LVEF of 36% to 50%, cardiac resynchronization therapy is reasonable to reduce total mortality, reduce hospitalizations, and improve symptoms and quality of life (2A recommendation1; Figure 3). This is an update from the 2013 guidelines in which this recommendation was limited to patients with LVEF ≤35%, undergoing device implantation with anticipated ventricular pacing (>40%).2
Figure 3. Algorithm to assess for eligibility of cardiac resynchronization therapy (CRT) implantation as per 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America guidelines for management of heart failure. ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; and SGLT-2, sodium glucose transporter-2.
The expansion of this recommendation is based on the BLOCK-HF trial (Biventricular Versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block) that demonstrated superiority of cardiac resynchronization therapy over conventional right ventricle only pacing in patients with New York Heart Association class I to III heart failure, LVEF ≤50%, and atrioventricular block.3 Patients enrolled in this trial were randomized to right ventricular pacing or cardiac resynchronization therapy, and there was a reduction in the primary outcome of death, urgent HF visit, or 15% increase in LV end systolic volume in the cardiac resynchronization therapy arm.
Article Information

References

1.
Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022;28:e1–e167. doi: 10.1016/j.cardfail.2022.02.010
2.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al; American College of Cardiology Foundation. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–e239. doi: 10.1016/j.jacc.2013.05.019
3.
Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T, Sutton MSJ; Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585–1593. doi: 10.1056/NEJMoa1210356https://www.ahajournals.org/journal/circheartfailure

Information & Authors

Information

Published In

Go to Circulation: Heart Failure
Go to Circulation: Heart Failure
Circulation: Heart Failure
Pages: e010118
PubMed: 37192293

History

Published in print: May 2023
Published online: 16 May 2023

Permissions

Request permissions for this article.

Keywords

  1. amlodipine
  2. catheterization
  3. coronary artery disease
  4. electrocardiography
  5. syncope

Authors

Affiliations

Reading Hospital, Drexel University College of Medicine, West Reading, PA (R.H.).
Gini Priyadharshini Jeyashanmugaraja, MD https://orcid.org/0000-0002-5784-6774
Yale New Haven Health Bridgeport Hospital, CT (G.P.J.).
Advanced Heart Failure Center, Oklahoma Heart Institute, Tulsa (S.C.S.).

Notes

For Disclosures, see page 458.
Correspondence to: Steven C. Stroud, MD, Advanced Heart Failure Center, Oklahoma Heart Institute, 1120 S Utica Ave, Tulsa, OK 74104. Email [email protected]

Disclosures

Disclosures None.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

View Options

View options

PDF and All Supplements

Download PDF and All Supplements

PDF/EPUB

View PDF/EPUB
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to access the full text.

Purchase access to this journal for 24 hours

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Figures

Tables

Media

Share

Share

Share article link

Share

Comment Response